|
Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
Feb 2025 |
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
Jul 2024 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Controversies on the Consequences of Iron Overload and Chelation in MDS |
May 2020 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) |
May 2024 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes with ring sideroblasts |
Oct 2023 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
|
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
Jul 2020 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
|
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria |
Mar 2024 |
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Outpatient transfusions for myelodysplastic syndromes |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Therapy for lower-risk MDS |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
